Compare peptides side-by-side
Pick any two peptides to compare their evidence quality, FDA approval status, research scores, risks, and indications. All data sourced from the SmartPeptide library.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
CJC-1295 / Ipamorelin
Growth-hormone secretagogue combination studied for stimulating endogenous GH pulses in research contexts.
Full pageBoth compounds have pharmacology data in healthy adults showing increased endogenous GH pulses without affecting prolactin or cortisol much. Some PK/PD trials are published.
Outcome trials (body composition, recovery, longevity) are sparse and mostly small. Long-term safety of repeated GH stimulation is not well established.
Carries risks similar to elevated GH (insulin resistance, edema). Not approved for general use.
Water retention, injection-site irritation, headaches.
Sermorelin
GHRH analog (first 29 amino acids of human GHRH). Stimulates endogenous growth hormone release. Approved for pediatric GH deficiency, widely used off-label in adults.
Full pagePediatric GH deficiency: FDA approved (now discontinued for marketing in the US but evidence stands). Stimulates GH/IGF-1 release in healthy adults short-term.
Adult anti-aging use, body recomposition, and long-term safety. Most clinic-marketed indications are NOT FDA-approved.
Hyperglycemia, fluid retention, hypothyroidism risk, possible carpal tunnel symptoms. Long-term cancer risk theoretical but understudied.
Injection-site reactions, headache, flushing, transient sleepiness, dizziness.